Ymmunobio Signs Collaboration Agreement with YUMAB
RIEHEN, Switzerland — Ymmunobio to optimize its antibody development with YUMAB’s antibody technology Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, today announced that it has signed a collaboration agreement with YUMAB GmbH, a privately-held German biotechnology company.
YUMAB provides technologies and contract research for the development of fully human antibodies for all therapeutic fields. Within the scope of the collaboration, Ymmunobio AG will complement its antibody development by utilizing YUMAB’s expertise and platform for optimizing its antibodies.
“We look forward to our collaboration being a productive complement to our capabilities,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. “Ymmunobio shares a commitment with YUMAB to accelerate drug development through antibody optimization.”
“We’re excited by the prospect of working with Ymmunobio to facilitate new pathways to antibody development,” said Dr. Thomas Schirrmann, YUMAB founder and CEO. “Ymmunobio shares our vision to accelerate drug discovery and ultimately improve patient outcomes.”
Ymmunobio is developing a proprietary class of CEACAM1 immune agonistic antibodies in order to employ the immune system to fight cancer. Financial conditions of the agreement were not disclosed.
Contact: Dr. Katrin Rupalla, email@example.com
About YMMUNOBIO Ymmunobio AG, a preclinical stage oncology biotech company, was founded by Dr. Katrin Rupalla and is committed to developing a proprietary class of CEACAM antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets defined CEACAM receptor isoforms that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany.
About YUMAB YUMAB GmbH, a leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies, was founded in 2012 by scientists of the University of Braunschweig. A global player in human monoclonal antibody development, YUMAB is focused on the use of fully human antibodies for immunotherapies. For more information, please visit www.yumab.com.